About Connext
Connext is a company based in Yeongcheon-si (South Korea) founded in 2017. It operates as a HealthTech and Licensing Model. Connext has raised $9.93 million across 1 funding round from investors including Pharmaresearch. Connext offers products and services including CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase). Connext operates in a competitive market with competitors including Moderna, BridgeBio, BeiGene, Spark Therapeutics and Rhythm Pharmaceuticals, among others.
- Headquarter Yeongcheon-si, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Connext Co., Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.93 M (USD)
in 1 rounds
-
Latest Funding Round
$9.93 M (USD), Series C
Mar 16, 2026
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Connext
Connext offers a comprehensive portfolio of products and services, including CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase).
Developed to prevent side effects in cancer treatments.
Designed to treat Dupuytren's contracture and related conditions.
Funding Insights of Connext
Connext has successfully raised a total of $9.93M through 1 strategic funding round. The most recent funding activity was a Series C round of $9.93 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Connext
Connext has secured backing from 1 investor. Prominent investors backing the company include Pharmaresearch.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Connext
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Connext
Investment portfolio details for Connext
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Connext
Detailed financials for Connext
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Connext Comparisons
Peer comparison for Connext
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Connext
Connext operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, BeiGene, Spark Therapeutics and Rhythm Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Connext
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Connext
Complete news archive for Connext
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Connext
Connext was founded in 2017 and raised its 1st funding round 9 years after it was founded.
Connext is headquartered in Yeongcheon-si, South Korea. It is registered at Yeongcheon-si, North Gyeongsang Province, South Korea.
Woo-Jong Lee is the current CEO of Connext.
Connext is a funded company, having raised a total of $9.93M across 1 funding round to date.
Connext, a clinical-stage bioventure, is focused on the development of biopharmaceuticals aimed at enhancing quality of life. Innovative drugs are being developed to prevent side effects from cancer and radiation therapies using recombinant TLR5 agonist technology. Additionally, the worlds first recombinant collagenase treatment is under development for conditions like Dupuytrens contracture. The company is expanding its pipeline in immuno-oncology and regenerative medicine sectors. Efforts are made to introduce, develop, and commercialize cutting-edge biotechnologies for global health impact.
Connext's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Connext offers CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase).
Connext has 1 investor. Key investors include Pharmaresearch.